Pfizer Inc. (PFE)
What changed in recent filings
- Revenue +3% YoYQuarter ended Jun 28, 2026
- Institutions — 2 new · 1 added · 1 reduced13F · as of end of 2026 Q2
- Free cash flow declined recentlyDec 31, 2025 → Jun 28, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Pfizer Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 4, 2026Revenue +2.6% YoY · EPS $-0.04Released before the open: Aug 3 close → Aug 4 close, the stock moved +1.5% · over the same window, market +1.8% · sector -0.2%
- 26Q1Released May 5, 2026Revenue +5.4% YoY · EPS $0.47Released before the open: May 4 close → May 5 close, the stock moved +0.6% · over the same window, market +0.8% · sector -0.2%
- 25Q4Released Feb 3, 2026Revenue -1.2% YoY · EPS $-0.29Released before the open: Feb 2 close → Feb 3 close, the stock moved -3.3% · over the same window, market -0.8% · sector -0.8%
- 25Q3Released Nov 4, 2025Revenue -5.9% YoY · EPS $0.62Released before the open: Nov 3 close → Nov 4 close, the stock moved -1.5% · over the same window, market -1.2% · sector +0.1%
The next earnings release is estimated around Nov 3, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Pfizer Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 4 → 2026 Q2: 8 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Pfizer Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Pzena Investment Management0.42% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.23% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.01% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors0.06% of portfolio · held as of 2020 Q3 or earlier
- GQG Partners0.01% of portfolio · since 2025 Q3
- Tudor Investment CorpNew this quarter0.02% of portfolio · since 2026 Q2
- Bridgewater AssociatesNew this quarter0.02% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Pfizer Inc. is classified under the Biotech & Health sector. See peers below.
Pfizer Inc. key financials
Based on SEC filings · as of Jun 28, 2026
Tap a metric name to see its meaning in the glossary.
Pfizer Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
PFE revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-28 revenue was $15.0B, +2.6% YoY.
The largest segment is United States, 58.9% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the International Developed Markets segment (about 92% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
PFE segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
4 quarters with a different segment breakdown were omitted (filing basis changed).
ETFs holding Pfizer Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
PFE on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
PFE FAQ
What is Pfizer Inc. (PFE)?
A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.
What sector is Pfizer Inc. in?
Pfizer Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Pfizer Inc.'s key financials?
As of Jun 28, 2026 in SEC filings: Revenue growth (YoY) -0.2%, Net margin 6.8%, ROE 9.0%, Debt-to-equity 0.71x. Definitions and interpretation are available on Stocklore.
What are Pfizer Inc.'s main revenue segments?
The largest segment is United States, about 58.9% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Pfizer Inc. (PFE) stock?
On Stocklore you can see PFE's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.